Biohaven Ltd. ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and ...

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell ...

TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...

From 2025 to 2030, the market will add USD 1.8 billion in new value, driven primarily by cryogenic separation systems. Steel production growth and the rising demand for high-purity gases will push ...

Reaffirms full-year 2025 Revenue guidance of $61.0 to $64.0 billion. Raises and narrows Adjusted (2) diluted EPS guidance (1) ...

Software & Services revenue grows 41% to $305 million Annual recurring revenue grows 41% to $1.3 billion Net loss was $2 million, with non-GAAP net income of $98 million and Adjusted EBITDA of $177 ...

After the advent of ChatGPT, the use of large language models (LLMs) has become increasingly widespread worldwide. LLMs are ...

The demand for the petrochemicals is driven by its extensive use across industries such as packaging, automotive, ...

NFRA releases Audit Practice Toolkit focusing on Strategy and Planning to enhance audit quality, especially for small and medium practitioners in ...

UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

A recent study from Oregon State University estimated that more than 3,500 animal species are at risk of extinction because ...